The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Arena Pharmaceuticals Receives Additional Patent

08-Apr-2015 | Source : Arena Pharmaceuticals | Visits : 6039
SAN DIEGO and WOODCLIFF LAKE, N.J. - Arena Pharmaceuticals Inc. and Eisai Inc., announced that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ® (lorcaserin HCl), a serotonin 2C receptor agonist approved for weight management.

"Seeking strong intellectual property protection has always been a key component of Arena's business model," said Jack Lief, Arena's President and Chief Executive Officer. "We expect this new patent to extend exclusivity for BELVIQ until 2033."

According to Arena Pharmaceuticals, in addition to this method-of-treatment patent, composition of matter patents for BELVIQ are issued in major jurisdictions globally that, in most cases, are capable of continuing into 2023. Arena has filed applications for patent term extension on patents directed to composition of matter in the United States, which, if granted, would extend the composition of matter patent term for BELVIQ into 2026 or potentially 2027.

BELVIQ is a serotonin 2C receptor agonist indicated in the United States as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m2 or greater (obese), or BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes. 

Related Articles